11/7
07:30 am
xoma
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Low
Report
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
10/23
08:18 am
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
10/22
08:00 am
xoma
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Low
Report
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
9/23
06:30 am
xoma
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
Low
Report
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
9/23
05:30 am
xoma
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Low
Report
XOMA Royalty Declares Quarterly Preferred Stock Dividends
9/20
01:29 pm
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
Medium
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
9/4
07:30 am
xoma
XOMA Royalty to Present at Upcoming Investor Conferences in September
Medium
Report
XOMA Royalty to Present at Upcoming Investor Conferences in September